Potential therapeutic targets in polyglutamine-mediated diseases

References

• La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 2010;11(4):247-58
   PubMed Web of Science ®Google Scholar
• Katsuno M, Banno H, Suzuki K, et al. Molecular genetics and biomarkers of polyglutamine diseases. Curr Mol Med 2008;8(3):221-34
   Google Scholar
• Rüb U, Schöls L, Paulson H, et al. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol 2013;104:38-66
   PubMed Web of Science ®Google Scholar
• Suga N, Katsuno M, Koike H, et al. Schwann cell involvement in the peripheral neuropathy of spinocerebellar ataxia type 3. Neuropathol Appl Neurobiol 2014;40(5):628-39
   Google Scholar
• Lalić NM, Dragasević N, Stefanova E, et al. Impaired insulin sensitivity and secretion in normoglycemic patients with spinocerebellar ataxia type 1. Mov Disord 2010;25(12):1976-80
   Google Scholar
• Bauer PO, Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 2009;110(6):1737-65
   PubMed Web of Science ®Google Scholar
• Chen S, Ferrone FA, Wetzel R. Huntington’s disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci USA 2002;99(18):11884-9
   Google Scholar
• Skibinski GA, Boyd L. Ubiquitination is involved in secondary growth, not initial formation of polyglutamine protein aggregates in C. elegans. BMC Cell Biol 2012;13:10
   Google Scholar
• Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431(7010):805-10
   PubMed Web of Science ®Google Scholar
• Romero E, Cha GH, Verstreken P, et al. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 2008;57(1):27-40
   Google Scholar
• Todd TW, Lim J. Aggregation formation in the polyglutamine diseases: protection at a cost? Mol Cells 2013;36(3):185-94
   Google Scholar
• Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998;95(1):55-66
   PubMed Web of Science ®Google Scholar
• Peters MF, Nucifora FC Jr, Kushi J, et al. Nuclear targeting of mutant Huntingtin increases toxicity. Mol Cell Neurosci 1999;14(2):121-8
   PubMed Web of Science ®Google Scholar
• Cowin RM, Roscic A, Bui N, et al. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington’s disease transgenic mouse. Behav Brain Res 2012;229(2):308-19
   Google Scholar
• Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002;35(5):843-54
   PubMed Web of Science ®Google Scholar
• Nagai Y, Inui T, Popiel HA, et al. A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol 2007;14(4):332-40
   Google Scholar
• Chen HK, Fernandez-Funez P, Acevedo SF, et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 2003;113(4):457-68
   Google Scholar
• Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10(1):83-98
   PubMed Web of Science ®Google Scholar
• Pennuto M, Palazzolo I, Poletti A. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum Mol Genet 2009;18(R1):R40-7
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Sutton L, Hayden MR. Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 2011;17(5):475-92
   Google Scholar
• Kaplan A, Stockwell BR. Therapeutic approaches to preventing cell death in Huntington disease. Prog Neurobiol 2012;99(3):262-80
   PubMed Web of Science ®Google Scholar
• Sadri-Vakili G, Cha JH. Mechanisms of disease: histone modifications in Huntington’s disease. Nat Clin Pract Neurol 2006;2(6):330-8
   PubMedGoogle Scholar
• Nucifora FC Jr, Sasaki M, Peters MF, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001;291(5512):2423-8
   PubMed Web of Science ®Google Scholar
• Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413(6857):739-43
   PubMed Web of Science ®Google Scholar
• Song W, Chen J, Petrilli A, et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med 2011;17(3):377-82
   PubMed Web of Science ®Google Scholar
• Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006;127(1):59-69
   PubMed Web of Science ®Google Scholar
• Panov AV, Gutekunst CA, Leavitt BR, et al. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 2002;5(8):731-6
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Harmison GG, Meyertholen K, et al. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet 2009;18(1):27-42
   PubMed Web of Science ®Google Scholar
• Chou AH, Yeh TH, Kuo YL, et al. Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL. Neurobiol Dis 2006;21(2):333-45
   Google Scholar
• Parsons MP, Raymond LA. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 2014;82(2):279-93
   PubMed Web of Science ®Google Scholar
• Hassel B, Tessler S, Faull RL, Emson PC. Glutamate uptake is reduced in prefrontal cortex in Huntington’s disease. Neurochem Res 2008;33(2):232-7
   Google Scholar
• Fan J, Cowan CM, Zhang LY, et al. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington’s disease. J Neurosci 2009;29(35):10928-38
   Google Scholar
• Puddifoot C, Martel MA, Soriano FX, et al. PGC-1α negatively regulates extrasynaptic NMDAR activity and excitotoxicity. J Neurosci 2012;32(20):6995-7000
   Google Scholar
• Wong YC, Holzbaur EL. The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation. J Neurosci 2014;34(4):1293-305
   PubMed Web of Science ®Google Scholar
• Katsuno M, Tanaka F, Adachi H, et al. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 2012;99(3):246-56
   PubMed Web of Science ®Google Scholar
• Giuliano P, De Cristofaro T, Affaitati A, et al. DNA damage induced by polyglutamine-expanded proteins. Hum Mol Genet 2003;12(18):2301-9
   Google Scholar
• Bertoni A, Giuliano P, Galgani M, et al. Early and late events induced by polyQ-expanded proteins: identification of a common pathogenic property of polYQ-expanded proteins. J Biol Chem 2011;286(6):4727-41
   Google Scholar
• Enokido Y, Tamura T, Ito H, et al. Mutant huntingtin impairs Ku70-mediated DNA repair. J Cell Biol 2010;189(3):425-43
   Google Scholar
• Xiao H, Yu Z, Wu Y, et al. A polyglutamine expansion disease protein sequesters PTIP to attenuate DNA repair and increase genomic instability. Hum Mol Genet 2012;21(19):4225-36
   Google Scholar
• Fujita K, Nakamura Y, Oka T, et al. A functional deficiency of TERA/VCP/p97 contributes to impaired DNA repair in multiple polyglutamine diseases. Nat Commun 2013;4:1816
   Google Scholar
• Custer SK, Garden GA, Gill N, et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci 2006;9(10):1302-11
   Google Scholar
• Bradford J, Shin JY, Roberts M, et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009;106(52):22480-5
   Google Scholar
• Monks DA, Johansen JA, Mo K, et al. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci USA 2007;104(46):18259-64
   PubMed Web of Science ®Google Scholar
• Cortes CJ, Ling SC, Guo LT, et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron 2014;82(2):295-307
   PubMed Web of Science ®Google Scholar
• Nedelsky NB, Pennuto M, Smith RB, et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 2010;67(6):936-52
   PubMed Web of Science ®Google Scholar
• Lim J, Crespo-Barreto J, Jafar-Nejad P, et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008;452(7188):713-18
   Google Scholar
• Yamanaka T, Nukina N. Transcription factor sequestration by polyglutamine proteins. Methods Mol Biol 2010;648:215-29
   Google Scholar
• Warrick JM, Morabito LM, Bilen J, et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell 2005;18(1):37-48
   PubMed Web of Science ®Google Scholar
• Novak MJ, Tabrizi SJ. Huntington’s disease: clinical presentation and treatment. Int Rev Neurobiol 2011;98:297-323
   PubMed Web of Science ®Google Scholar
• Marmolino D, Manto M. Past, present and future therapeutics for cerebellar ataxias. Curr Neuropharmacol 2010;8(1):41-61
   PubMed Web of Science ®Google Scholar
• Brusse E, Maat-Kievit JA, van Swieten JC. Diagnosis and management of early- and late-onset cerebellar ataxia. Clin Genet 2007;71(1):12-24
   Google Scholar
• Katsuno M, Adachi H, Doyu M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003;9(6):768-73
   PubMed Web of Science ®Google Scholar
• Banno H, Katsuno M, Suzuki K, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 2009;65(2):140-50
   PubMed Web of Science ®Google Scholar
• Katsuno M, Banno H, Suzuki K, et al. Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(9):875-84
   PubMed Web of Science ®Google Scholar
• Fernández-Rhodes LE, Kokkinis AD, White MJ, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 2011;10(2):140-7
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Duennwald M, Markovic P, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington’s disease models. Hum Mol Genet 2006;15(18):2743-51
   PubMed Web of Science ®Google Scholar
• Sontag EM, Lotz GP, Agrawal N, et al. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington’s disease models. J Neurosci 2012;32(32):11109-19
   PubMed Web of Science ®Google Scholar
• Appl T, Kaltenbach L, Lo DC, Terstappen GC. Targeting mutant huntingtin for the development of disease-modifying therapy. Drug Discov Today 2012;17(21-22):1217-23
   Google Scholar
• Bodner RA, Outeiro TF, Altmann S, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington’s and Parkinson’s diseases. Proc Natl Acad Sci USA 2006;103(11):4246-51
   Google Scholar
• Palazzolo I, Nedelsky NB, Askew CE, et al. B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy. J Neurosci Res 2010;88(10):2207-16
   PubMed Web of Science ®Google Scholar
• Sarkar S, Rubinsztein DC. Huntington’s disease: degradation of mutant huntingtin by autophagy. FEBS J 2008;275(17):4263-70
   PubMed Web of Science ®Google Scholar
• Katsuno M, Sang C, Adachi H, et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci USA 2005;102(46):16801-6
   PubMed Web of Science ®Google Scholar
• Malik B, Nirmalananthan N, Gray AL, et al. Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy. Brain 2013;136(Pt 3):926-43
   PubMed Web of Science ®Google Scholar
• Wang AM, Miyata Y, Klinedinst S, et al. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol 2013;9(2):112-18
   PubMed Web of Science ®Google Scholar
• Waza M, Adachi H, Katsuno M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005;11(10):1088-95
   PubMed Web of Science ®Google Scholar
• Fujikake N, Nagai Y, Popiel HA, et al. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 2008;283(38):26188-97
   PubMed Web of Science ®Google Scholar
• Tokui K, Adachi H, Waza M, et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 2009;18(5):898-910
   PubMed Web of Science ®Google Scholar
• Wong HK, Bauer PO, Kurosawa M, et al. Blocking acid-sensing ion channel 1 alleviates Huntington’s disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum Mol Genet 2008;17(20):3223-35
   PubMed Web of Science ®Google Scholar
• Chort A, Alves S, Marinello M, et al. Interferon β induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice. Brain 2013;136(Pt 6):1732-45
   Google Scholar
• Montie HL, Cho MS, Holder L, et al. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2009;18(11):1937-50
   Google Scholar
• Doi H, Adachi H, Katsuno M, et al. p62/SQSTM1 differentially removes the toxic mutant androgen receptor via autophagy and inclusion formation in a spinal and bulbar muscular atrophy mouse model. J Neurosci 2013;33(18):7710-27
   PubMed Web of Science ®Google Scholar
• Tanaka M, Machida Y, Niu S, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004;10(2):148-54
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004;36(6):585-95
   PubMed Web of Science ®Google Scholar
• Menzies FM, Huebener J, Renna M, et al. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 2010;133(Pt 1):93-104
   PubMed Web of Science ®Google Scholar
• Rusmini P, Simonini F, Crippa V, et al. 17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. Neurobiol Dis 2011;41(1):83-95
   PubMed Web of Science ®Google Scholar
• Bauer PO, Wong HK, Oyama F, et al. Inhibition of Rho kinases enhances the degradation of mutant huntingtin. J Biol Chem 2009;284(19):13153-64
   PubMed Web of Science ®Google Scholar
• Tohnai G, Adachi H, Katsuno M, et al. Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy. Hum Mol Genet 2014;23(13):3552-65
   PubMed Web of Science ®Google Scholar
• Nisoli I, Chauvin JP, Napoletano F, et al. Neurodegeneration by polyglutamine Atrophin is not rescued by induction of autophagy. Cell Death Differ 2010;17(10):1577-87
   PubMed Web of Science ®Google Scholar
• Yu Z, Wang AM, Adachi H, et al. Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice. PLoS Genet 2011;7(10):e1002321
   PubMed Web of Science ®Google Scholar
• Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 2006;7(10):784-96
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J Neurosci 2003;23(28):9418-27
   PubMed Web of Science ®Google Scholar
• Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004;13(11):1183-92
   PubMed Web of Science ®Google Scholar
• Chou AH, Chen SY, Yeh TH, et al. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol Dis 2011;41(2):481-8
   PubMed Web of Science ®Google Scholar
• Ying M, Xu R, Wu X, et al. Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J Biol Chem 2006;281(18):12580-6
   Google Scholar
• Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Natl Acad Sci USA 2003;100(4):2041-6
   PubMed Web of Science ®Google Scholar
• Yi J, Zhang L, Tang B, et al. Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4. PLoS One 2013;8(1):e54792
   Google Scholar
• Apostol BL, Simmons DA, Zuccato C, et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci 2008;39(1):8-20
   PubMed Web of Science ®Google Scholar
• Minamiyama M, Katsuno M, Adachi H, et al. Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. Nat Med 2012;18(10):1531-8
   PubMed Web of Science ®Google Scholar
• Pattison LR, Kotter MR, Fraga D, Bonelli RM. Apoptotic cascades as possible targets for inhibiting cell death in Huntington’s disease. J Neurol 2006;253(9):1137-42
   Google Scholar
• Okamoto S, Pouladi MA, Talantova M, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 2009;15(12):1407-13
   PubMed Web of Science ®Google Scholar
• Hourez R, Servais L, Orduz D, et al. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci 2011;31(33):11795-807
   PubMed Web of Science ®Google Scholar
• Perroud B, Jafar-Nejad P, Wikoff WR, et al. Pharmacometabolomic signature of ataxia SCA1 mouse model and lithium effects. PLoS One 2013;8(8):e70610
   PubMed Web of Science ®Google Scholar
• Saute JA, de Castilhos RM, Monte TL, et al. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord 2014;29(4):568-73
   PubMed Web of Science ®Google Scholar
• Giampà C, Montagna E, Dato C, et al. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington’s disease. PLoS One 2013;8(5):e64037
   Google Scholar
• Jiang M, Peng Q, Liu X, et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington’s disease. Hum Mol Genet 2013;22(12):2462-24670
   PubMed Web of Science ®Google Scholar
• Pineda JR, Pardo R, Zala D, et al. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington’s disease. Mol Brain 2009;2:33
   Google Scholar
• Simmons DA, Rex CS, Palmer L, et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington’s disease knockin mice. Proc Natl Acad Sci USA 2009;106(12):4906-11
   PubMed Web of Science ®Google Scholar
• Palazzolo I, Stack C, Kong L, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009;63(3):316-28
   PubMed Web of Science ®Google Scholar
• Rinaldi C, Bott LC, Chen KL, et al. Insulin-like growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. Mol Med 2012;18:1261-8
   PubMed Web of Science ®Google Scholar
• Tsunemi T, La Spada AR. PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington’s disease to Parkinson’s disease and beyond. Prog Neurobiol 2012;97(2):142-51
   PubMed Web of Science ®Google Scholar
• Johri A, Calingasan NY, Hennessey TM, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington’s disease. Hum Mol Genet 2012;21(5):1124-37
   Google Scholar
• Jin J, Albertz J, Guo Z, et al. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington’s disease. J Neurochem 2013;125(3):410-19
   Google Scholar
• Hathorn T, Snyder-Keller A, Messer A. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington’s disease. Neurobiol Dis 2011;41(1):43-50
   Google Scholar
• Huntington Study Group. Available from: www.huntington-study-group.org/Home/tabid/36/Default.aspx [Last accessed 10 May 2014]
   Google Scholar
• Pearce I, Heathfield KW, Pearce MJ. Valproate sodium in Huntington chorea. Arch Neurol 1977;34(5):308-9
   Google Scholar
• Symington GR, Leonard DP, Shannon PJ, Vajda FJ. Sodium valproate in Huntington’s disease. Am J Psychiatry 1978;135(3):352-4
   Google Scholar
• Landwehrmeyer GB, Dubois B, de Yébenes JG, et al. Riluzole in Huntington’s disease: a 3-year, randomized controlled study. Ann Neurol 2007;62(3):262-72
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79(6):597-603
   PubMed Web of Science ®Google Scholar
• Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004;10(8):816-20
   PubMed Web of Science ®Google Scholar
• DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 2007;104(43):17204-9
   PubMed Web of Science ®Google Scholar
• Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol Ther 2009;17(6):1053-63
   PubMed Web of Science ®Google Scholar
• Lieberman AP, Yu Z, Murray S, et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep 2014;7(3):774-84
   PubMed Web of Science ®Google Scholar
• Hu J, Gagnon KT, Liu J, et al. Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biol Chem 2011;392(4):315-25
   Google Scholar
• Benraiss A, Goldman SA. Cellular therapy and induced neuronal replacement for Huntington’s disease. Neurotherapeutics 2011;8(4):577-90
   PubMed Web of Science ®Google Scholar
• Grote HE, Bull ND, Howard ML, et al. Cognitive disorders and neurogenesis deficits in Huntington’s disease mice are rescued by fluoxetine. Eur J Neurosci 2005;22(8):2081-8
   PubMed Web of Science ®Google Scholar
• Lazic SE, Grote HE, Blakemore C, et al. Neurogenesis in the R6/1 transgenic mouse model of Huntington’s disease, effects of environmental enrichment. Eur J Neurosci 2006;23(7):1829-38
   Google Scholar
• Cho SR, Benraiss A, Chmielnicki E, et al. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest 2007;117(10):2889-902
   Google Scholar
• Peng Q, Masuda N, Jiang M, et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington’s disease mouse model. Exp Neurol 2008;210(1):154-63
   Google Scholar
• Duan W, Peng Q, Masuda N, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington’s disease. Neurobiol Dis 2008;30(3):312-22
   Google Scholar
• Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci 1998;11(4):234-45
   PubMed Web of Science ®Google Scholar
• Popiel HA, Takeuchi T, Fujita H, et al. Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism. PLoS One 2012;7(11):e51069
   Google Scholar
• Miyazaki Y, Adachi H, Katsuno M, et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med 2012;18(7):1136-41
   PubMed Web of Science ®Google Scholar
• Pang TY, Stam NC, Nithianantharajah J, et al. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington’s disease transgenic mice. Neuroscience 2006;141(2):569-84
   PubMed Web of Science ®Google Scholar
• van Dellen A, Cordery PM, Spires TL, et al. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington’s disease. BMC Neurosci 2008;9:34
   Google Scholar
• van Dellen A, Blakemore C, Deacon R, et al. Delaying the onset of Huntington’s in mice. Nature 2000;404(6779):721-2
   PubMed Web of Science ®Google Scholar
• Fryer JD, Yu P, Kang H, et al. Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science 2011;334(6056):690-3
   Google Scholar
• Harrison DJ, Busse M, Openshaw R, et al. Exercise attenuates neuropathology and has greater benefit on cognitive than motor deficits in the R6/1 Huntington’s disease mouse model. Exp Neurol 2013;248:457-69
   PubMed Web of Science ®Google Scholar
• Preisler N, Andersen G, Thøgersen F, et al. Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). Neurology 2009;72(4):317-23
   Google Scholar
• Hockly E, Cordery PM, Woodman B, et al. Environmental enrichment slows disease progression in R6/2 Huntington’s disease mice. Ann Neurol 2002;51(2):235-42
   PubMed Web of Science ®Google Scholar
• Nithianantharajah J, Barkus C, Murphy M, Hannan AJ. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington’s disease transgenic mice. Neurobiol Dis 2008;29(3):490-504
   PubMed Web of Science ®Google Scholar
• McOmish CE, Hannan AJ. Enviromimetics, exploring gene environment interactions to identify therapeutic targets for brain disorders. Expert Opin Ther Targets 2007;11(7):899-913
   PubMed Web of Science ®Google Scholar
• Mo C, Pang TY, Ransome MI, et al. High stress hormone levels accelerate the onset of memory deficits in male Huntington’s disease mice. Neurobiol Dis 2014;69:248-62
   Google Scholar
• Zhang Y, Long JD, Mills JA, PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet 2011;156B(7):751-63
   Google Scholar
• Paulsen JS, Smith MM, Long JD; PREDICT HD investigators and Coordinators of the Huntington Study Group. Cognitive decline in prodromal Huntington Disease: implications for clinical trials. J Neurol Neurosurg Psychiatry 2013;84(11):1233-9
   Google Scholar
• Tabrizi SJ, Scahill RI, Owen G, et al. TRACK-HD Investigators. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12(7):637-49
   PubMed Web of Science ®Google Scholar
• Chandra A, Johri A, Beal MF. Prospects for neuroprotective therapies in prodromal Huntington’s disease. Mov Disord 2014;29(3):285-93
   Google Scholar
• Rosas HD, Doros G, Gevorkian S, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 2014;82(10):850-7
   PubMed Web of Science ®Google Scholar
• McCusker EA, Myers RH. Feasibility of Huntington disease trials in the disease prodrome. Neurology 2014;82(10):824-5
   Google Scholar
• Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014;10(4):204-16
   PubMed Web of Science ®Google Scholar
• Aylward EH, Nopoulos PC, Ross CA, et al. PREDICT-HD Investigators and Coordinators of Huntington Study Group. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011;82(4):405-10
   Google Scholar
• Mascalchi M, Diciotti S, Giannelli M, et al. Progression of brain atrophy in spinocerebellar ataxia type 2: a longitudinal tensor-based morphometry study. PLoS ONE 2014;9(2):e89410
   Google Scholar
• Poudel GR, Stout JC, Domínguez D JF, et al. White matter connectivity reflects clinical and cognitive status in Huntington’s disease. Neurobiol Dis 2014;65:180-7
   Google Scholar
• Paulsen JS, Zimbelman JL, Hinton SC, et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington’s Disease. AJNR Am J Neuroradiol 2004;25(10):1715-21
   PubMed Web of Science ®Google Scholar
• Ferraro S, Nanetti L, Piacentini S, et al. Frontal cortex BOLD signal changes in premanifest Huntington disease: a possible fMRI biomarker. Neurology 2014;83(1):65-72
   Google Scholar
• Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med 2006;47(2):215-22
   Google Scholar
• Pavese N, Andrews TC, Brooks DJ, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study. Brain 2003;126(5):1127-35
   PubMed Web of Science ®Google Scholar
• Tai YF, Pavese N, Gerhard A, et al. Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain 2007;130(7):1759-66
   Google Scholar
• Killoran A, Biglan KM. 8-OHdG: its (limited) potential as a biomarker for Huntington’s disease. Biomark Med 2012;6(6):777-80
   Google Scholar
• Mano T, Katsuno M, Banno H, et al. Cross-sectional and longitudinal analysis of an oxidative stress biomarker for spinal and bulbar muscular atrophy. Muscle Nerve 2012;46(5):692-7
   Google Scholar
• Leoni V, Long JD, Mills JA, PREDICT-HD study group. Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol Dis 2013;55:37-43
   Google Scholar
• Varani K, Abbracchio MP, Cannella M, et al. Aberrant A2A receptor function in peripheral blood cells in Huntington’s disease. Faseb J 2003;17(44):2148-50
   Google Scholar
• Maglione V, Giallonardo P, Cannella M, et al. Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington’s disease. Am J Med Genet B Neuropsychiatr Genet 2005;139B(1):101-5
   PubMedGoogle Scholar
• Varani K, Bachoud-Levi AC, Mariotti C, et al. Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington’s disease stages. Neurobiol Dis 2007;27(1):36-43
   Google Scholar
• Dalrymple A, Wild EJ, Joubert R, et al. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 2007;6(7):2833-40
   PubMed Web of Science ®Google Scholar
• Hu Y, Chopra V, Chopra R, et al. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci USA 2011;108(41):17141-6
   PubMed Web of Science ®Google Scholar
• Moscovitch-Lopatin M, Weiss A, Rosas HD, et al. Optimization of an HTRF assay for the detection of soluble mutant huntingtin in human buffy coats: a potential biomarker in blood for Huntington disease. PLoS Curr 2010;2:RRN1205
   Google Scholar
• Weiss A, Träger U, Wild EJ, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression. J Clin Invest 2012;122(10):3731-6
   PubMed Web of Science ®Google Scholar
• Reilmann R, Bohlen S, Klopstock T, et al. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington’s disease. Mov Disord 2010;25(13):2195-202
   Google Scholar
• Mano T, Katsuno M, Banno H, et al. Tongue pressure as a novel biomarker of spinal and bulbar muscular atrophy. Neurology 2014;82(3):255-62
   Google Scholar
• Blekher T, Johnson SA, Marshall J, et al. Saccades in presymptomatic and early stages of Huntington disease. Neurology 2006;67(3):394-9
   Google Scholar
• Rodríguez-Labrada R, Velázquez-Pérez L, Seigfried C, et al. Saccadic latency is prolonged in Spinocerebellar Ataxia type 2 and correlates with the frontal-executive dysfunctions. J Neurol Sci 2011;306(1-2):103-7
   Google Scholar
• Suzuki K, Katsuno M, Banno H, et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008;131(Pt 1):229-39
   PubMed Web of Science ®Google Scholar
• Katsuno M, Tanaka F, Sobue G. Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2012;83(3):329-35
   Google Scholar
• Krauss S, Griesche N, Jastrzebska E, et al. Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex. Nat Commun 2013;4:1511
   PubMed Web of Science ®Google Scholar
• Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 1985;44(6):559-77
   PubMed Web of Science ®Google Scholar